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Introduction: This pooled analysis was performed to examine the
impact of pretreatment factors on severe (grade 3 or higher) adverse
events (AE) in patients with advanced stage non-small cell lung
cancer (NSCLC).
Methods: A pooled data set of 1053 participants from nine North
Central Cancer Treatment Group clinical trials was used. Age,
gender, performance status, tumor stage, body mass index, serum
creatinine levels, hemoglobin levels, white blood cell counts, and
platelet counts were evaluated univariately and multivariately using
logistic regression. The magnitude of the effects of the pretreatment
factors after adjusting for type of chemotherapy agent (platinum
versus no platinum) was explored in the final multivariate model.
Results: Women and older participants had a significantly greater
risk for experiencing severe hematologic and non-hematologic AE.
Participants with performance status 0 had an increased risk for
severe non-hematologic AE. For every one unit (109/L) increase in
pretreatment white blood cell count, there was an 11% reduction in
the odds of experiencing a severe hematologic AE. The magnitude
of these effects on the end points remained similar after adjusting for
type of chemotherapy agent.
Conclusions: Pretreatment factors of gender, age, performance
status, and hematologic parameters were significant predictors of
severe AE among patients with advanced stage NSCLC. This
suggests the need to control or adjust for factors that predispose
patients to an increased risk of severe AE. These findings can aid in
tailoring therapy to individual patients and in the proper design of
future clinical trials.
KeyWords: Adverse events, Multivariate modeling, Non-small cell
lung cancer, Pooled analysis.
(J Thorac Oncol. 2006;1: 556–563)
Multi-agent chemotherapy is the standard treatment formedically fit patients with advanced stage (stage IIIB
with malignant pleural effusion and stage IV) non-small cell
lung cancer (NSCLC). Unfortunately, the outcome of patients
with advanced NSCLC is generally poor, and treatment
seems to have a very modest effect on overall survival. A
large meta-analysis demonstrated a 2-month increase in me-
dian survival after platinum-based therapy and an absolute
10% improvement in the 1-year survival rate compared with
best supportive care.1
Treatment-related adverse events (AE) (or toxicities)
are common after systemic chemotherapy for advanced NSCLC.
In our clinical experience, chemotherapy for lung cancer has a
reputation for toxicity that is worrisome to patients to the point
that some decide not to pursue chemotherapy because of the fear
of side effects.2 This problem has also been noted in patient-
oriented information sources (http://www.cancerguide.org/
sideeffect, http://www.cancernausea.com; accessed March
18, 2006). Each agent has specific toxicities, but the most
common are related to bone marrow suppression, fatigue,
nausea, vomiting, anorexia, and neuropathies. It is therefore
important to evaluate toxicity not only to gain insights into
the effects of treatment but also to understand those factors
that predispose patients to increased toxicity.
In clinical trials of cancer therapy, toxicity is generally
reported for each patient cohort treated with a specific regi-
men. Often, the patient-related factors that predispose for
toxicity are not evaluated. Specific detailed knowledge of the
factors that predispose patients to toxicity is critically impor-
tant in determining how best to treat individual patients and
for the proper design of future clinical trials. Some factors
shown to be associated with increased toxicity in patients
with lung cancer include the use of multiple agents (as
opposed to single agents), patient gender, weight loss, use of
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regimens containing cisplatin (as opposed to non-cisplatin–
containing regimens).
To further identify specific pretreatment factors that
predispose patients to AE, we performed a pooled analysis of
nine clinical trials of chemotherapy given as first-line treat-
ment for advanced (stage IIIB with malignant pleural effusion
and stage IV) NSCLC. Our objective was to investigate the
impact of pretreatment factors on the incidence of severe
(grade 3 or higher; grade 3) hematologic and non-hemato-
logic AE regardless of study treatment. The magnitude of the
effects of the significant pretreatment factors on AE outcome
was further assessed after adjusting for type of chemotherapy
agent (platinum versus no platinum).
METHODS
Trial Characteristics
Individual study participants’ data were pooled across
first-line NCCTG chemotherapy trials for advanced NSCLC
that opened between 1985 and 2001. Seven patients who
never received any study treatment were excluded from all
analyses. Platinum-containing regimens were administered in
46% of patients and 56% of trials. Five of the trials assigned
numerical grades to treatment-related AE using National
Cancer Institute Common Toxicity Criteria (CTC) version
1.0, two trials used CTC version 2.0, and two trials were
conducted before CTC came into use. See Table 1 for a
detailed listing of the individual trial characteristics.25–33
End Points
Severe non-hematologic (non-heme) AE was defined as
any grade 3 or greater non-hematologic AE (non-heme 3
AE) that was attributed by the original investigators as being
at least possibly related to the study therapy using the CTC
version used by the study protocol. This included all AE,
except those associated with the hematologic system. Only
the treatment-related AE as attributed by the original inves-
tigator were assessed for this end point because studies
performed before CTC version 2.0 recorded only those AE
that were at least possibly related to the study therapy.
Severe hematologic (heme) AE was defined as any
grade 3 or greater hematologic adverse event regardless of
relationship to the study therapy (heme 3 AE). These
included anemia, thrombocytopenia, neutropenia, and leuko-
penia. The grades of heme AEs were determined retrospec-
tively by applying CTC version 3.0 to the actual counts
recorded during the conduct of the studies. Hence, this
analysis could include all heme AEs, not just those attributed
by the original investigator as being treatment-related. The
grade 4 and grade 5 heme and non-heme AE end points
were not explored because of an insufficient number of such
events.
Statistical Analysis
A logistic regression model adjusted for individual trial
effect to capture between trial variations was used for the
univariate and multivariate analyses. The pretreatment factors
considered for inclusion in the multivariate models were age,
TABLE 1. Individual Trial Characteristics
Protocol 85225125,26 87245127 88245228 89245129 92245330 932451c 95245231 98245232 N002633
n 147 113 100 242 78 83 34 106 157
Excluded 0 2 0 1 2 0 0 2 0
Date opened 07/05/85 06/11/87 12/09/88 05/03/90 04/16/93 08/26/94 11/20/96 02/19/99 08/10/01
Date closed 08/21/90 08/17/88 03/15/91 10/23/92 11/11/93 06/04/96 05/15/98 01/26/01 05/27/03
Phase III III II III II II II II II
CTC version Pre-CTC Pre-CTC CTC v.1 CTC v.1 CTC v.1 CTC v.1 CTC v.1 CTC v.2 CTC v.2
ECOG Performance status 0–3 0–2 0–1 0–2 0–2 0–1 0–2 0–1 0–1
Stage IIIB/IV IV IV IIIB/IV IIIB/IV IIIB/IV IIIB/IV IIIB/IV IIIB/IV
Weight loss criteria No
exclusions
No
exclusions
No
exclusions
10% in
3 months
excluded
10% in
2 months
excluded
10% in
2 months
excluded
Body Surface
Area  2.3
10% in
3 months
excluded
10% in
6 weeks
excluded
Agents A: Mitomycin,
Vinblastine,
Cisplatin
B: Mitomycin
A: bolus
Etoposide 
Cisplatin
B: Infusion
Etoposide 
Cisplatin
A: Amonafide
B: Trimetrexate
A: Cisplatin,
Etoposide,
Hydrazine
sulfate
B: Cisplatin,
Etoposide
A/B:
Topotecan
A: Cisplatin,
Topotecan,
Filgrastim
B: Topotecan,
Paclitaxel,
Filgrastim
A: EVAC2/
Filgrastim
A/B/C:
Docetaxel,
Gemcitabine
A/B/C:
Alimta,
Gemcitabine
Factors collected Hgb Yes Yes Yes Yes Yes Yes Yes Yes Yes
at baseline WBC Yes Yes Yes Yes Yes Yes Yes Noa Noa
PLT Yes Yes Yes Yes Yes Yes Yes Yes Yes
Creatinine Yes Yes Yes Yes Nob Nob Nob Yes Yes
BMI Yes Yes Yes Yes Yes Yes Yes Yes Yes
CTC, Common Toxicity Criteria; EVAC, edatrexate in combination with vinblastine, adriamycin, and cisplatin; Hgb, hemoglobin; WBC, white blood cells; PLT, platelets; BMI,
body mass index. aAbsolute neutrophil count was collected instead of WBC. bCreatinine required to be within institutional normal limits for eligibility; actual values were not
collected. cUnpublished data.
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gender, Eastern Cooperative Oncology Group (ECOG)-de-
fined performance status (PS), American Joint Committee on
Cancer (AJCC)-defined disease stage, body mass index
(BMI), white blood count (WBC), hemoglobin level (Hgb),
platelet count (PLT), and serum creatinine (Cr). All pretreat-
ment hematologic parameters were included in the multivar-
iate model for the heme 3 AE end point, regardless of their
significance to appropriately adjust for all the baseline blood
count measurements while estimating the probability of ex-
periencing a heme 3 AE. Other factors of potential interest,
such as smoking status and co-morbidities, were not collected
and hence not evaluated
The factors that were significant in the univariate set-
ting were further assessed in the multivariate setting. All
two-way interactions of the main effects were evaluated in
the multivariate models. The magnitude of the effect of the
pretreatment factors after adjusting for type of chemotherapy
agent (platinum versus no platinum) was explored by adding
this term to the final multivariate model unadjusted for trial
effect (because the trial effect was confounded with the type
of chemotherapy agent). Analyses were performed on the
complete data available based on the selected covariates for
the respective end point.
The log-linear assumption was tested for all the con-
tinuous factors using graphical (plot of log odds versus
midpoints of the quartiles of the continuous variables) and
statistical techniques (Box-Tidwell transformation).3 All fac-
tors were tested for between-trial heterogeneity. Diagnostic
plots and sensitivity analysis were conducted to explore the
influence of individual patient data on the overall model
outcomes. The final models were selected using stepwise
regression modeling techniques. Forward and backward re-
gression procedures were also explored and provided identi-
cal results. All tests were two-sided, with p values 0.05 for
main effects and p values 0.01 for interaction terms denot-
ing statistical significance. Odds ratios (ORs) and the asso-
ciated 95% confidence intervals (CI) were calculated.
Model discrimination was evaluated using the area
under the receiver-operating characteristic (ROC) curve, with
values 0.70 considered acceptable.3 Model calibration was
evaluated using the Hosmer and Lemeshow’s goodness-of-fit
test.4 This test compares the observed and expected number
of events within each decile of risk, in which the first decile
contains patients with the lowest risk for the event and the last
decile contains patients with the highest risk for the event.
The final multivariate models were further assessed using
bootstrap techniques (stratified samples with replacement
from the original data set). The same model development
process as outlined above was applied to each of the 1000
data sets to assess the stability.5 The percentage of times a
factor was selected as a significant factor in the multivariate
model is reported. Factors selected more than 70% of the time
(a cutoff used in other regression settings) were considered
stable.6
RESULTS
Data were frozen on February 11, 2005 and included a
total of 1053 patients. Two trials (98-24-52 and N0026) were
not included in the multivariate analyses for the heme 3 AE
end point because the absolute neutrophil count (ANC) rather
than WBC values were recorded at baseline. Additionally, the
two pre-CTC trials (85-22-51 and 87-24-51) in which non-
heme AE were not collected were not included in the univar-
iate or multivariate analyses for the non-heme 3 AE end
point.
Baseline Participant Characteristics
Table 2 provides a detailed description of characteris-
tics for all 1053 participants in the trials, the cohort of 787
evaluable for the multivariate analyses of the heme 3 AE
end point, and the cohort of 795 used in the univariate and
multivariate analyses of the non-heme 3 AE end point. The
baseline characteristics of the participants included in
the multivariate models for both end points were similar to
the characteristics of the participants from the entire cohort.
Summary of AE Outcomes
The percentage of participants with at least one heme
3 AE ranged from 29.3% to 73.5% across all trials, whereas
the percentage of participants experiencing at least one non-
heme 3 AE ranged from 17.1% to 59.8% (Table 3). There
were a total of 10 treatment-related grade 5 adverse events.
These included infection (seven participants), renal failure
(two participants), and pneumonitis (one participant). The
seven participants who had a grade 5 infection also experi-
enced a grade 4 leukopenia during the same cycle. Table 4
summarizes the most common (5% or greater within grade 3
category) grade 3 adverse events. These include leukopenia
(46%), neutropenia (21%), nausea (12%), lethargy (10%),
vomiting (10%), fatigue (7%), and anorexia (5%).
Univariate Analyses
Age and gender were significant predictors for both the
grade 3 heme and non-heme end points and were further
assessed in the multivariate setting. PS was a significant
predictor for the non-heme 3 AE and was included in the
multivariate analyses for that end point. Cr, BMI, and stage
were not significant predictors for either end point in the
univariate setting and thus were not explored further. The
pretreatment hematologic parameters (WBC, Hgb, PLT) were
included in the multivariate heme 3 AE model regardless of
their significance univariately. See Table 5 for the univariate
results.
Multivariate Analyses
All factors that were significant predictors in the uni-
variate setting were also significant predictors in the multi-
variate setting. Table 6 gives the OR estimates (along with
the 95% CI), and the p values from the final model for the
heme 3 and non-heme 3 AE end points. Older partici-
pants and women had a significantly higher risk of experi-
encing heme 3 and non-heme 3 AEs. Participants with a
PS 0 had a significantly higher risk of experiencing a
non-heme 3 AE. Each increase of one unit (109/L) in WBC
count resulted in an 11% reduction in the odds of experienc-
ing a heme 3 AE. None of the two-way interactions were
significant in the multivariate models. The magnitude of the
effects of age, gender, PS, and hematologic parameters on the
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respective end points remained similar after adjusting for the
type of chemotherapy agent (platinum versus no platinum).
An equation based on the final multivariate models to predict
an individual patient’s risk for severe heme or non-heme AE
is given in Appendix I.
Model Diagnostics
All continuous factors satisfied the linearity assumption
for both end points. All factors except age satisfied the
homogeneity assumption for both end points.
The heterogeneity test for age was qualitative for heme
3 AE, i.e., in five of the seven trials, age had an OR 1.0
(consistent with the overall age effect), but in two trials
(88-24-52 and 95-24-52), the OR for age was 1.0 (not
statistically significant). Because the effect of age was mostly
in the same direction across trials, including age in our final
model for heme 3 AE was considered reasonable.
The area under the ROC curves for heme 3 and
non-heme 3 AE were 0.75 and 0.71, respectively, suggest-
ing an acceptable discrimination. Both models had a good
calibration based on the Hosmer and Lemeshow goodness-
of-fit test (p  0.41 and p  0.98 for the non-heme and heme
models, respectively). The bootstrap results indicated that the
model selection process was very stable. Age and gender
were selected as a significant predictor 99.6% and 77.5% (in
the 1000 bootstrap models) of the times, respectively, for
heme 3 AE. In the case of non-heme 3 AE, gender, PS,
and age were selected as significant predictors in 91.4%,
TABLE 2. Participant Characteristics
Cohort 1 (n  1053)a Cohort 2 (n  795)b Cohort 3 (n  787)c
Factor n (%) n (%) n (%)
Age (yr) Median (range) 64 (31–85) 64 (31–85) 64 (31–85)
PS 0 283 (26.9) 243 (30.6) 194 (24.7)
1 633 (60.1) 489 (61.5) 458 (58.2)
2 128 (12.2) 63 (7.9) 126 (16.0)
3 9 (0.9) 0 (0.0) 9 (1.1)
Gender M 695 (66.0) 515 (64.8) 525 (66.7)
F 358 (34.0) 280 (35.2) 262 (33.3)
Stage IIIB 135 (12.8) 121 (15.2) 88 (11.2)
IV 913 (86.7) 673 (84.7) 694 (88.2)
Missing 5 (0.5) 1 (0.1) 5 (0.6)
BMI (kg/m2) Median (range) 24.9 (10.6–46.0) 25.3 (10.6–46.0) 24.6 (10.6–45.5)
Missing 6 (0.6) 6 (0.8) 4 (0.5)
WBC (109/L) Median (range) 9.1 (4.3–38.0) 8.9 (4.3–38.0) 9.0 (4.3–38.0)
Missingd 262 (24.9) 262 (33.0) 0 (0.0)
Hgb (109/L ) Median (range) 13.3 (6.9–18.9) 13.4 (6.9–18.9) 13.2 (6.9–18.9)
Missing 1 (0.1) 1 (0.1) 0 (0.0)
PLT (109/L) Median (range) 3.48 (1.17–9.56) 3.43 (1.17–9.56) 3.55 (1.26–9.53)
Missing 6 (0.6) 3 (0.4) 0 (0.0)
Cr (ULN) Median (range) 1.0 (0.1–2.3) 1.0 (0.1–2.3) 1.0 (0.2–1.9)
Missinge 195 (18.5) 194 (24.4) 194 (24.7)
Hgb, hemoglobin; WBC, white blood cells; PLT, platelets; BMI, body mass index; Cr, creatinine. aCohort of patients used in univariate analysis of heme end point. bCohort of
patients used for non-heme end point (univariate and multivariate analysis). cCohort of patients used in multivariate analysis of heme end point. dAbsolute neutrophil count was
collected instead of WBC in two trials. eCreatinine required to be within institutional normal limits for eligibility in three trials; actual values were not collected.
TABLE 3. Summary of Adverse Events by Trial
Protocol Heme 3 Non-heme 3 Heme 4 Non-Heme 4
852251 29.3% 6.8%
872451 68.5% 26.1%
882452 32.0% 22.0% 8.0% 3.0%
892451 58.9% 59.8% 17.8% 10.8%
922453 69.7% 17.1% 40.8% 2.6%
932451 57.8% 31.3% 32.5% 13.3%
952452 73.5% 52.9% 55.9% 26.5%
982452 51.0% 55.8% 28.9% 11.5%
N0026 72.6% 57.3% 31.9% 11.5%
Overall 55.7% 46.7% 23.5% 10.2%
TABLE 4. Summary of most frequently (5% or greater
within grade 3 category) occurring adverse events
AE Grade 3 Grade 4
Leukopenia 32% 14%
Neutropenia 10% 11%
Nausea 12% 0%
Lethargic 9% 1%
Vomiting 7% 3%
Anorexia 5% 0%
Fatigue 6% 1%
AE, adverse advents.
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71.3%, and 70.8% (in the 1000 bootstrap models) of the
times, respectively.
DISCUSSION
This study identified pretreatment factors of gender,
age, PS, and hematologic parameters as important predictors
of severe AE in patients with advanced stage NSCLC treated
with first-line chemotherapy. An interesting and previously
unexplored finding is that the magnitude of the effects of
these factors on the respective end points remained similar
after adjusting for the type of chemotherapy agent (platinum
versus no platinum). These pretreatment factors being inde-
pendent predictors of AE outcomes regardless of the treat-
ment received is somewhat contrary to the working hypoth-
esis that non-platinum regimens are less toxic than platinum
regimens for higher risk populations. Platinum-containing
regimens were administered in 46% of patients and 56% of
the trials considered in this analysis.
Emerging data suggest that gender-specific pharmaco-
kinetics and toxicity exist for certain chemotherapeutic drugs.
Previous studies have revealed that major factors responsible
for gender-dependent pharmacokinetics are related to differ-
ences in body composition, renal elimination, drug absorp-
tion, and hepatic function.7 Gender-related differences in
clearance rates and AUC ratios have been reported for doxo-
rubicin and etoposide.8,9 Similarly, it has been shown that the
clearance of fluorouracil is lower in women than in men,10
resulting in gender-related differences in drug toxicity.11–13
TABLE 5. Univariate Results
Grade 3 Heme (n  1053)a Grade 3 Non-Heme (n  795)b
Factor Odds ratio p value 95% confidence limits Odds ratio p value 95% confidence limits
Age (yr) (10-yr increase) (1.48) 0.0001 (1.28, 1.71) 1.20 0.03 (1.02, 1.40)
Gender
Male (1.00) — — (1.00) — —
Female (1.36) 0.03 (1.03, 1.79) (1.66) 0.002 (1.21, 2.27)
PS
0 (1.00) — — (1.00) — —
1 (0.83) 0.23 (0.62, 1.12) (1.38) 0.06 (0.99, 1.92)
2/3 (0.89) 0.62 (0.56, 1.42) (2.17) 0.02 (1.14, 4.12)
Stage
IIIB (1.00) — — (1.00) — —
IV (1.11) 0.60 (0.75, 1.63) (1.00) 0.98 (0.67, 1.52)
BMI (kg/m2) (10-unit increase) (1.31) 0.06 (0.99, 1.73) (1.31) 0.09 (0.96, 1.78)
WBC (109/L) (1-unit increase) (0.88) 0.0001 (0.84, 0.92) (0.99) 0.57 (0.94, 1.04)
Hgb (g/dL) (1-unit increase) (1.02) 0.71 (0.94, 1.10) (0.98) 0.58 (0.89, 1.07)
PLT (109/L) (1-unit increase) (0.81) 0.0001 (0.73, 0.89) (1.07) 0.29 (0.95, 1.20)
Creatinine (ULN) (1-unit increase) (1.50) 0.15 (0.86, 2.60) (0.79) 0.44 (0.43, 1.45)
Hgb, hemoglobin; WBC, white blood cells; PLT, platelets; BMI, body mass index. aRegardless of relationship to study therapy. bAt least possibly related to study therapy.
TABLE 6. Multivariate Results
Grade 3 Hemea Grade 3 Non-Hemeb
Factor Odds ratio p value 95% confidence limits Odds ratio p value 95% confidence limits
Age (yr) (10-yr increase) (1.50) 0.0001 (1.26, 1.78) (1.23) 0.01 (1.04, 1.44)
Gender
Male (1.00) — — (1.00) — —
Female (1.60) 0.007 (1.14, 2.26) (1.71) 0.0009 (1.25, 2.35)
PS
0 — — — (1.00) — —
1 — — — (1.44) 0.03 (1.03, 2.00)
2/3 — — — (2.29) 0.01 (1.20, 4.39)
WBC (109/L) (1-unit increase) (0.89) 0.0001 (0.85, 0.94) — — —
Hgb (g/dL) (0.95) 0.28 (0.86, 1.05) — — —
PLT (109/L) (0.92) 0.22 (0.80, 1.05) — — —
Hgb, hemoglobin; WBC, white blood cells; PLT, platelets. aRegardless of relationship to study therapy. bAt least possibly related to study therapy.
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Although few gender-related studies of cisplatin therapy have
been undertaken, at least one study has shown that women
experience significantly more cisplatin-induced nausea and
vomiting.14,15
Investigators at the National Cancer Institute of Canada
(NCIC) recently performed a retrospective analysis examin-
ing associations between gender and outcome.16 This study
included patients from four phase III small cell lung cancer
trials and found that women experience more frequent and
more severe toxicity than men from chemotherapy. Literature
supports the observation that age is related to the likelihood
of severe hematologic and non-hematologic chemotherapy-
induced toxicities. A recent retrospective analysis of the
Eastern Cooperative Oncology Group (ECOG) study 5592,
which randomly assigned patients with advanced NSCLC to
receive cisplatin with either etoposide or paclitaxel, assessed
likelihood of toxicity based on age. This analysis revealed
that men older than 70 years experienced significantly more
severe leukopenia and neuropsychiatric toxicities, and
women older than 70 years were significantly more likely to
experience severe weight loss and leukopenia compared with
their younger counterparts.17 Our data support this conclusion
that gender and age are important factors in the rate and
severity of both hematologic and non-hematologic toxicity
resulting from chemotherapy.
Two groups have shown that docetaxel pharmacokinet-
ics are similar in older and younger patients, suggesting that
an age-related susceptibility to chemotherapy-induced bone
marrow injury, rather than altered drug metabolism or clear-
ance, causes older patients to experience more profound
hematologic toxicities for this agent.18,19 However, both lim-
ited marrow reserve and decreased drug clearance in the
elderly may contribute to the greater risk for AE with certain
chemotherapeutic agents.
The value of pretreatment PS as a prognostic factor in
NSCLC is well known.20,21 However, the utility of PS as a
predictor of toxicities has not been previously noted. An
analysis of toxicity data with respect to pretreatment PS was
performed by the investigators of the trial (ECOG 1594), in
which patients with advanced NSCLC were randomized to
receive paclitaxel/cisplatin, gemcitabine/cisplatin, docetaxel/
cisplatin, or paclitaxel/carboplatin. This analysis revealed no
difference in the incidence of worst grade toxicities in pa-
tients with a PS of 2 compared with patients with a PS of 0
or 1.22 Our observations regarding the effect of pretreatment
PS stand in contrast to these findings. The differences can
possibly be attributed to: 1) only 46% of the patients in our
pooled analysis population received platinum-containing reg-
imens; 2) we evaluated all heme adverse events regardless of
attribution to study treatment; and 3) we evaluated the PS 
0 and PS  1 group separately and only combined the few
PS  3 patients with the PS  2 patients.
The observation that pretreatment WBC is a predictor
of severe hematologic toxicity in treatment of patients with
NSCLC has not, to our knowledge, been previously reported.
Specifically, for every one unit (109/L) increase in pretreat-
ment WBC, there was an 11% reduction in the odds of
experiencing a severe hematologic AE. However, this is not
a surprising result, given that the pretreatment WBC likely
provides an assessment of bone marrow vitality and resil-
ience.
The present analyses revealed that age, gender, and
WBC were associated with severe hematologic AE, and age,
gender, and PS were associated with severe non-hematologic
AE. These findings can have implications for future clinical
trial design. Optimally, phase I trials could be designed with
these findings in mind. The maximally tolerated dose (MTD)
of a particular therapy could be determined with a single
cohort and then verified or redefined with patient subgroups
having different AE risk factors before opening large trials.
For example, phase I trials that only include younger men
with good PS and favorable hematologic characteristics
would likely determine a MTD that may be quite different
than trials with older women with limited PS and less favor-
able hematologic parameters. The prediction equation in the
appendix could also be used to define these subgroups or to
predict a MTD. These findings also have implications for the
subsequent phase II and III trials in which the chemotherapy
doses administered could be based on the MTD for different
patient subgroups. It is possible that future trials incorporat-
ing these ideas would provide less variation in toxicity and
fewer treatment-related deaths. The goal of tailoring the dose
for an individual patient may be obtainable.
In summary, our analysis has identified gender, age,
pretreatment PS, and hematologic parameters (specifically,
pretreatment WBC count) as important predictors of severe
AE among patients with advanced stage NSCLC.
The homogeneity assumption was satisfied for each
prognostic factor, indicating that the magnitude and direction
of the effect of the factor was similar across trials, which
demonstrates the consistency in the relationships observed
over time and across trials including a variety of treatments.
In terms of clinical research, the prediction equation can be
used to estimate the probability of experiencing a severe
heme or non-heme toxicity by different subgroups of patients
based on their pretreatment factors and compare it with the
observed toxicity in these subgroups. This would allow one to
more accurately gauge the toxicity profile of the treatment
regimen itself. Our analysis could also be applied to better
predict which patients would benefit from advances in use of
supportive measures such as more effective or more effec-
tively scheduled use of hematopoietic growth factors, anti-
emetic therapies, anti-fatigue treatments, and the like. Thus,
in addition to selecting patients for more focused toxicity
surveillance, patients identified to be at risk of greater toxicity
could be targeted for earlier and more aggressive use of
supportive interventions. However, independent validation of
the prognostic importance of the pretreatment factors identi-
fied in this analysis, as well as other factors of interest, such
as smoking status and co-morbidities, is necessary before it can
be incorporated into routine clinical practice. In addition, further
refinement of the prediction equation is also needed as new
prognostic (genetic and clinical) factors become available.
Despite the introduction of newer agents and combina-
tions into the management of advanced lung cancer, most of
the common toxicities of our therapies (cytopenias, nausea,
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vomiting, lethargy, anorexia) remain the same. Ultimately, it
will be important to validate the equations with data derived
from populations receiving these newer therapies, but it is our
bias that these equations may predict to a large extent the AE
from newer chemotherapy as well. The present analyses can
predict an individual patient’s risk for experiencing a severe
AE based on their own pretreatment factors. Considerable
research is focused on identifying the genetic basis of che-
motherapy toxicity. For example, mutation of one such gene
(UGT1A1) has been identified as predictive of toxicity in
patients receiving irinotecan.23,24 Identification of additional
genetic predictors of chemotherapy toxicity will allow greater
individualization of therapy. Ultimately, these genetic indi-
cators may supplant the clinical parameters, such as those
identified in the present study, in tailoring therapy to the
individual.
APPENDIX I
Predicted probability of experiencing an adverse event 
eg(x)
1 eg(x)
Severe non-hematologic adverse event
(at least possibly related to study regimen):
g(x) 
(1.93) 
(0 if male) Or (0.54 if female) 
(0.02  age in years) 
(0 if PS  0) or (0.36 if PS  1) Or
(0.83 if PS  2 or 3)
Example
The predicted probability of experiencing a non-heme
grade 3 adverse event (at least possibly related to the study
regimen) for a woman who is 63 years old with a PS of 1 is:
g(x)  1.93  0.54  0.02  63  0.36  0.23
Therefore, the predicted probability estimate for this
patient is:
eg(x)
1 eg(x)
e0.23
1 e0.23 56%
Severe hematologic adverse events (regardless
of attribution):
g(x) 
(0.41) 
(0.11  WBC value in 109/L) 
(0.05  Hgb value in g/dL) 
(0.09  PLT value in 109/L) 
(0.04  age in years) 
(0 if male) or (0.47 if female)
Example
The predicted probability of experiencing a Heme
grade 3 adverse event (regardless of attribution) for a man
who is 72 years old and who has values of 14, 13, and 4 for
WBC, Hgb, and PLT, respectively, is:
g(x)  0.41  0.11 14  0.05  13  0.09  4  0.04
 72  0.08
eg(x)
1 eg(x)
e0.08
1 e0.08 48%
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